Bryan E. Jones, P. Brown-Augsburger, K. Corbett, Kathryn Westendorf, J. Davies, T. Cujec, C. Wiethoff, J. Blackbourne, B. Heinz, Denisa Foster, R. Higgs, D. Balasubramaniam, L. Wang, Roza Bidshahri, Lucas Kraft, Yuri Hwang, Stefanie Žentelis, K. Jepson, R. Goya, Maia A. Smith, David W Collins, Samuel J. Hinshaw, Sean A. Tycho, D. Pellacani, Ping Xiang, Krithika Muthuraman, S. Sobhanifar, Marissa H. Piper, Franz J. Triana, J. Hendle, A. Pustilnik, A. Adams, Shawn J Berens, R. Baric, D. R. Martinez, R. Cross, T. Geisbert, V. Borisevich, Olubukola M. Abiona, Hayley M. Belli, Maren de Vries, Adil Mohamed, Meike Dittmann, M. Samanovic, M. Mulligan, J. Goldsmith, C. Hsieh, Nicole V. Johnson, D. Wrapp, J. McLellan, B. Barnhart, B. Graham, J. Mascola, Carl L. Hansen, E. Falconer
bioRxiv : the preprint server for biology, 2020
SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection. One Sentence Summary LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.
Cited by 74 publications.
Field of study: Biology